Bridget Maloney-Hall1, Sarah C Wallingford2, Sarah Konefal1, Matthew M Young1,3. 1. Canadian Centre on Substance Use and Addiction, Ottawa, Ontario, Canada. 2. Ottawa Public Health, Ottawa, Ontario, Canada. 3. Department of Psychology, Carleton University, Ottawa, Ontario, Canada.
Abstract
INTRODUCTION: Given the recent and impending changes to the legal status of nonmedical cannabis use in Canada, understanding the effects of cannabis use on the health care system is important for evaluating the impact of policy change. The aim of this study was to examine pre-legalization trends in hospitalizations for mental and behavioural disorders due to the use of cannabis, according to demographics factors and clinical conditions. METHODS: We assessed the total number of inpatient hospitalizations for psychiatric conditions with a primary diagnosis of a mental or behavioural disorder due to cannabis use (ICD-10-CA code F12) from the Hospital Mental Health Database for ten years spanning 2006 to 2015, inclusive. We included hospitalizations from all provinces and territories except Quebec. Rates (per 100 000 persons) and relative proportions of hospitalizations by clinical condition, age group, sex and year are reported. RESULTS: Between 2006 and 2015, the rate of cannabis-related hospitalizations in Canada doubled. Of special note, however, is that hospitalizations during this time period for those with the clinical condition code "mental and behavioural disorders due to use of cannabinoids, psychotic disorder" (F12.5) tripled, accounting for almost half (48%) of all cannabis-related hospitalizations in 2015. CONCLUSION: Further research is required to investigate the reasons for the increase in hospitalizations for cannabis-related psychotic disorder. The introduction of high-potency cannabinoid products and synthetic cannabinoids into the illicit market are considered as possible factors.
INTRODUCTION: Given the recent and impending changes to the legal status of nonmedical cannabis use in Canada, understanding the effects of cannabis use on the health care system is important for evaluating the impact of policy change. The aim of this study was to examine pre-legalization trends in hospitalizations for mental and behavioural disorders due to the use of cannabis, according to demographics factors and clinical conditions. METHODS: We assessed the total number of inpatient hospitalizations for psychiatric conditions with a primary diagnosis of a mental or behavioural disorder due to cannabis use (ICD-10-CA code F12) from the Hospital Mental Health Database for ten years spanning 2006 to 2015, inclusive. We included hospitalizations from all provinces and territories except Quebec. Rates (per 100 000 persons) and relative proportions of hospitalizations by clinical condition, age group, sex and year are reported. RESULTS: Between 2006 and 2015, the rate of cannabis-related hospitalizations in Canada doubled. Of special note, however, is that hospitalizations during this time period for those with the clinical condition code "mental and behavioural disorders due to use of cannabinoids, psychotic disorder" (F12.5) tripled, accounting for almost half (48%) of all cannabis-related hospitalizations in 2015. CONCLUSION: Further research is required to investigate the reasons for the increase in hospitalizations for cannabis-related psychotic disorder. The introduction of high-potency cannabinoid products and synthetic cannabinoids into the illicit market are considered as possible factors.
Authors: Mahmoud A ElSohly; Zlatko Mehmedic; Susan Foster; Chandrani Gon; Suman Chandra; James C Church Journal: Biol Psychiatry Date: 2016-01-19 Impact factor: 13.382
Authors: Marco Colizzi; Conrad Iyegbe; John Powell; Gianluca Ursini; Annamaria Porcelli; Aurora Bonvino; Paolo Taurisano; Raffaella Romano; Rita Masellis; Giuseppe Blasi; Craig Morgan; Katherine Aitchison; Valeria Mondelli; Sonija Luzi; Anna Kolliakou; Anthony David; Robin M Murray; Alessandro Bertolino; Marta Di Forti Journal: Schizophr Bull Date: 2015-03-31 Impact factor: 9.306
Authors: José María Pelayo-Terán; Rocío Pérez-Iglesias; Ignacio Mata; Eugenio Carrasco-Marín; José Luis Vázquez-Barquero; Benedicto Crespo-Facorro Journal: Psychiatry Res Date: 2010-05-21 Impact factor: 3.222
Authors: Theresa H M Moore; Stanley Zammit; Anne Lingford-Hughes; Thomas R E Barnes; Peter B Jones; Margaret Burke; Glyn Lewis Journal: Lancet Date: 2007-07-28 Impact factor: 79.321
Authors: Avshalom Caspi; Terrie E Moffitt; Mary Cannon; Joseph McClay; Robin Murray; HonaLee Harrington; Alan Taylor; Louise Arseneault; Ben Williams; Antony Braithwaite; Richie Poulton; Ian W Craig Journal: Biol Psychiatry Date: 2005-05-15 Impact factor: 13.382
Authors: Marta Di Forti; Hannah Sallis; Fabio Allegri; Antonella Trotta; Laura Ferraro; Simona A Stilo; Arianna Marconi; Caterina La Cascia; Tiago Reis Marques; Carmine Pariante; Paola Dazzan; Valeria Mondelli; Alessandra Paparelli; Anna Kolliakou; Diana Prata; Fiona Gaughran; Anthony S David; Craig Morgan; Daniel Stahl; Mizanur Khondoker; James H MacCabe; Robin M Murray Journal: Schizophr Bull Date: 2013-12-17 Impact factor: 9.306
Authors: Suzanne Archie; Lena Palaniyappan; Andrew T Olagunju; Natasha Johnson; Nicole Kozloff; Elham Sadeh; Andrea Bardell; Alexandra Baines; Kelly K Anderson; Oyedeji Ayonrinde; Manuela Ferrari Journal: JMIR Res Protoc Date: 2022-05-20
Authors: Russell C Callaghan; Marcos Sanches; Robin M Murray; Sarah Konefal; Bridget Maloney-Hall; Stephen J Kish Journal: Can J Psychiatry Date: 2022-01-12 Impact factor: 5.321